Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tafasitamab-cxix
Synonyms
Therapy Description

MOR208 is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tafasitamab-cxix Monjuvi MOR00208|XmAb5574|MOR-208|MOR208 CD19 Antibody 9 Monjuvi (tafasitamab-cxix) is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329, PMID: 32511983). Monjuvi (tafasitamab-cxix) is FDA approved for use in combination with Revlimid (lenalidomide) in patients with relapsed or refractory diffuse large B cell lymphoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown diffuse large B-cell lymphoma not applicable Tafasitamab-cxix Phase II Actionable In a Phase II trial, diffuse large B-cell lymphoma patients tolerated Monjuvi (tafasitamab-cxix) treatment, and achieved an overall response rate of 26% (9/35, 2 complete and 7 partial response) with 5 patients responding over 12 months, a disease control rate of 40% (14/35), a median duration of response of 20.1 months and a progression-free survival of 2.7 months at a median follow-up of 21 months (PMID: 29444231; NCT01685008). 29444231
Unknown unknown mantle cell lymphoma no benefit Tafasitamab-cxix Phase II Actionable In a Phase II trial, Monjuvi (tafasitamab-cxix) treatment was well-tolerated and resulted in stable disease as the best response in 50% (6/12) of patients with mantle cell lymphoma (PMID: 29444231; NCT01685008). 29444231
Unknown unknown follicular lymphoma not applicable Tafasitamab-cxix Phase II Actionable In a Phase II trial, follicular lymphoma patients tolerated Monjuvi (tafasitamab-cxix) treatment, and achieved an overall response rate of 29% (10/34, 3 complete and 7 partial response) with 4 patients responding over 12 months, a disease control rate of 76% (26/34), progression-free survival of 8.8 months at a median follow-up of 21 months, and a median duration of response was not reached (PMID: 29444231; NCT01685008). 29444231
Unknown unknown marginal zone B-cell lymphoma not applicable Tafasitamab-cxix Phase II Actionable In a Phase II trial, Monjuvi (tafasitamab-cxix) treatment was well-tolerated, and resulted in 2 complete and 1 partial responses (n=9) in marginal zone lymphoma patients (PMID: 29444231; NCT01685008). 29444231

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status


Additional content available in CKB BOOST